目的 比较匹多莫德和脾氨肽对反复呼吸道感染( RRI)患儿的临床症状及Th1/Th2细胞因子的影响.方法 RRI患儿86例随机分为对照组和治疗组,在常规治疗基础上,分别给予脾氨肽和匹多莫德治疗,疗程均为3个月.比较两组患儿治疗前后上清液单核细胞的IL-4、IFN-γ水平,治疗期间难治性肺炎支原体肺炎(MPP)次数和临床症状(发热、咳嗽、扁桃体肿大和肺内啰音)持续时间以及治疗结束时的临床疗效.结果 与对照组比较,治疗组患儿治疗期间MPP次数显著降低(P＜0.01),临床症状持续时间显著缩短(P＜0.01),临床疗效显著优于对照组(P＜0.05).此外,治疗后两组患儿的的IL-4、IFN-γ水平差异具有统计学意义(P＜0.01).结论 匹多莫德治疗反复呼吸道感染患儿疗效优于脾氨肽,可能与调节Th1/Th2细胞因子平衡有关.%Purpose To compare the effect of pidotimod and spleen aminopeptide on clinical symptoms and Thl/Th2 cytokine in children with recurrent respiratory tract infection ( RRI). Methods 86 children with RRI were randomly divided into treatment group and control group. They received pidotimod and spleen aminopeptide respectively for 3 months besides routine treatment. The levels of interleukin-4 (IL-4) and interferon-γ( IFN-γ) in cultured supernatant peripheral blood mononuclear cells were compared before and after treatment. Times of MPP, duration of clinical symptoms ( fever, cough, antiadoncus and Lung NaLuo sound) during treatment, and clinical efficacy after treatment were compared. /Results Compared with control group, the times of MPP during treatment was significantly decreased ( P < 0.01) ,and the duration of clinical symptoms during treatment was significantly shortened (P < 0. 01 ) , and the clinical efficacy in treatment was significantly better than that in control group (P <0.05). Furthermore, the levels of IL-4 and IFN--y of both group were significantly different statistically ( P <0. 01 ) . Conclusion Pidotimod has better curative effect to children with RRI than spleen aminopeptide, probably related to modulating the balance of Thl/Th2 cytokine.
展开▼
